Fundies. English
Radiopharm Theranostics Limited
EDGAR92 filing records in this dataset, filed from 2024-12-05 to 2026-10-05. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 4.14 million uref_138071911 Source
Exact value
4138074 uref_138071911
- Long-term debt including current maturities
- Not available
- Shares outstanding
- Not available
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-05.
Financial data available through: 2026-06-30.
Coverage by financial measure
- Revenue: Multiple units; comparison withheld· newest 2026-06-30
- Operating income: 3 of 11 periods available· newest 2026-06-30
- net income: No compatible figures in this window
- Operating cash flow: 3 of 11 periods available· newest 2026-06-30
- Capital expenditure: 1 of 11 periods available· newest 2023-06-30
- Total assets: 2 of 11 periods available· newest 2026-06-30
- Total liabilities: 2 of 11 periods available· newest 2026-06-30
- Current assets: 2 of 11 periods available· newest 2026-06-30
- Current liabilities: 2 of 11 periods available· newest 2026-06-30
- Cash and cash equivalents: 4 of 11 periods available· newest 2026-06-30
- long term debt: No compatible figures in this window
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
No unambiguous prior-year comparison is available for the latest reporting period.
Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(uref_138071911) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2023-07-01 – 2024-06-30 | Unavailable Not reported for this period. | −uref_138071911 22.98 million Exact valueExact value: -22975935 uref_138071911 Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2024-07-01 – 2025-06-30 | Unavailable Not reported for this period. | −uref_138071911 36.65 million Exact valueExact value: -36645477 uref_138071911 Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2026 2025-07-01 – 2026-06-30 | Unavailable Not reported for this period. | −uref_138071911 52.78 million Exact valueExact value: -52782838 uref_138071911 Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
92 filings · 315 latest values · 315 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001949257, 1949257, RADX, edgar:1949257
Also known as RADIOPHARM THERANOSTICS LIMITED, Radiopharm Theranostics Limited, Radiopharm Theranostics Ltd